Targeted Immunosuppressive Therapeutics
Potential treatment option for neuromyelitis optica spectrum disorder (NMOSD)
AIM Biologicals utilize a novel mechanism which is believed to demonstrate that peptide antigens presented on immunosuppressive MHC class I molecules can selectively and efficiently induce antigen-specific tolerance. Based on this mechanism, the targeted immunosuppressive therapeutics are being designed as optimized soluble molecules with the goal that they may be adapted to selectively induce tolerance to various autoantigens.
During pregnancy, the maternal immune system tolerates paternal antigens from the embryo but is still effective to protect mother and embryo from foreign antigens. Parts of the natural mechanisms responsible for this feto-maternal immune tolerance form the scientific basis for the concept of AIM Biologicals.
Targeted, highly specific, autoimmunity modifying proteins
Technology derived from body’s natural process that protects a fetus from the mother’s immune system
Developed at leading research and teaching university
Pre-clinical studies conducted by the Julius-Maximilians-University thus far indicate that tolerance induction appears to be achieved via selective elimination of antigen-specific immune effector cells and via induction of antigen-specific regulatory T cells from naïve T cells.
Neuromyelitis Optica Spectrum Disorder (NMOSD)
people in the U.S.
NMOSD, also known as “Devic disease”, is a chronic autoimmune disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and of the spinal cord (myelitis).
50% of individuals will become wheelchair bound and blind
30% fatality within 5 years